Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

In the last 5 years, FDA has actively characterized innovative ECG analysis methods for proarrhythmia assessments in clinical trials. ECG is a cornerstone of cardiac safety monitoring in toxicology and safety pharmacology with similarities between clinical and non-clinical evaluations.

A presentation was given by CitoxLab North America during SOT Annual Meeting & ToxExpo 2019, in Baltimore:

Recent Advances in ECG Analysis for ProArrhythmia Risk Assessment: The Need to Read Between the Line

 

Other posts you may like

Happy Holidays from all of us at emka TECHNOLOGIES

Please take note that our offices will be closed during holidays. Consult the dates here.

Pharmacology 2019

December 15-17, 201 Edinburgh, UK Booth #14

Molecular Biology Society of Japan

December 03-06, 2019 Fukuoka, Japan

American Epilepsy Society

December 06-10, 2019 Baltimore, USA Booth #120